367 related articles for article (PubMed ID: 16950824)
1. Effects of weak acids, UV and proton motive force inhibitors on pyrazinamide activity against Mycobacterium tuberculosis in vitro.
Wade MM; Zhang Y
J Antimicrob Chemother; 2006 Nov; 58(5):936-41. PubMed ID: 16950824
[TBL] [Abstract][Full Text] [Related]
2. [Nutrient starved incubation conditions enhance pyrazinamide activity against Mycobacterium tuberculosis].
Chen ZF; Huang Q; Li YY; Zhang Y; Ren Y; Li KS; Fu ZJ; Xu SQ
Zhonghua Jie He He Hu Xi Za Zhi; 2007 May; 30(5):359-62. PubMed ID: 17651643
[TBL] [Abstract][Full Text] [Related]
3. Iron enhances the antituberculous activity of pyrazinamide.
Somoskovi A; Wade MM; Sun Z; Zhang Y
J Antimicrob Chemother; 2004 Feb; 53(2):192-6. PubMed ID: 14729751
[TBL] [Abstract][Full Text] [Related]
4. Nutrient-starved incubation conditions enhance pyrazinamide activity against Mycobacterium tuberculosis.
Huang Q; Chen ZF; Li YY; Zhang Y; Ren Y; Fu Z; Xu SQ
Chemotherapy; 2007; 53(5):338-43. PubMed ID: 17785970
[TBL] [Abstract][Full Text] [Related]
5. Mode of action of pyrazinamide: disruption of Mycobacterium tuberculosis membrane transport and energetics by pyrazinoic acid.
Zhang Y; Wade MM; Scorpio A; Zhang H; Sun Z
J Antimicrob Chemother; 2003 Nov; 52(5):790-5. PubMed ID: 14563891
[TBL] [Abstract][Full Text] [Related]
6. The curious characteristics of pyrazinamide: a review.
Zhang Y; Mitchison D
Int J Tuberc Lung Dis; 2003 Jan; 7(1):6-21. PubMed ID: 12701830
[TBL] [Abstract][Full Text] [Related]
7. [In vitro antimycobacterial activities of pyrazinamide analogs: results of screening tests].
Yamamoto S; Toida I; Watanabe N; Ura T
Kekkaku; 1996 Mar; 71(3):253-8. PubMed ID: 8901227
[TBL] [Abstract][Full Text] [Related]
8. Enhancement of the antituberculosis activity of weak acids by inhibitors of energy metabolism but not by anaerobiosis suggests that weak acids act differently from the front-line tuberculosis drug pyrazinamide.
Gu P; Constantino L; Zhang Y
J Med Microbiol; 2008 Sep; 57(Pt 9):1129-1134. PubMed ID: 18719183
[TBL] [Abstract][Full Text] [Related]
9. The paradox of pyrazinamide: an update on the molecular mechanisms of pyrazinamide resistance in Mycobacteria.
Singh P; Mishra AK; Malonia SK; Chauhan DS; Sharma VD; Venkatesan K; Katoch VM
J Commun Dis; 2006 Mar; 38(3):288-98. PubMed ID: 17373362
[TBL] [Abstract][Full Text] [Related]
10. Pyrazinamide inhibits the eukaryotic-like fatty acid synthetase I (FASI) of Mycobacterium tuberculosis.
Zimhony O; Cox JS; Welch JT; Vilchèze C; Jacobs WR
Nat Med; 2000 Sep; 6(9):1043-7. PubMed ID: 10973326
[TBL] [Abstract][Full Text] [Related]
11. [Studies on the effect of antituberculosis agents against tubercle bacilli in the resting state, using streptomycin-dependent strain (18-b). I. Studies in vitro].
Ota Y
Kekkaku; 1971 Aug; 46(8):295-301. PubMed ID: 4328204
[No Abstract] [Full Text] [Related]
12. Quantitative structure-activity relationships for the in vitro antimycobacterial activity of pyrazinoic acid esters.
Bergmann KE; Cynamon MH; Welch JT
J Med Chem; 1996 Aug; 39(17):3394-400. PubMed ID: 8765523
[TBL] [Abstract][Full Text] [Related]
13. Sterilising action of pyrazinamide in models of dormant and rifampicin-tolerant Mycobacterium tuberculosis.
Hu Y; Coates AR; Mitchison DA
Int J Tuberc Lung Dis; 2006 Mar; 10(3):317-22. PubMed ID: 16562713
[TBL] [Abstract][Full Text] [Related]
14. Lipophilic pyrazinoic acid amide and ester prodrugs stability, activation and activity against M. tuberculosis.
Simões MF; Valente E; Gómez MJ; Anes E; Constantino L
Eur J Pharm Sci; 2009 Jun; 37(3-4):257-63. PubMed ID: 19491013
[TBL] [Abstract][Full Text] [Related]
15. Pyrazinamide is not active against Mycobacterium tuberculosis residing in cultured human monocyte-derived macrophages.
Heifets L; Higgins M; Simon B
Int J Tuberc Lung Dis; 2000 Jun; 4(6):491-5. PubMed ID: 10864178
[TBL] [Abstract][Full Text] [Related]
16. Pyrazinamide sterilizing activity in vitro against semidormant Mycobacterium tuberculosis bacterial populations.
Heifets L; Lindholm-Levy P
Am Rev Respir Dis; 1992 May; 145(5):1223-5. PubMed ID: 1586071
[TBL] [Abstract][Full Text] [Related]
17. pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis clinical isolates from the southeast region of Brazil.
Barco P; Cardoso RF; Hirata RD; Leite CQ; Pandolfi JR; Sato DN; Shikama ML; de Melo FF; Mamizuka EM; Campanerut PA; Hirata MH
J Antimicrob Chemother; 2006 Nov; 58(5):930-5. PubMed ID: 16971417
[TBL] [Abstract][Full Text] [Related]
18. Pyrazinoic acid and its n-propyl ester inhibit fatty acid synthase type I in replicating tubercle bacilli.
Zimhony O; Vilchèze C; Arai M; Welch JT; Jacobs WR
Antimicrob Agents Chemother; 2007 Feb; 51(2):752-4. PubMed ID: 17101678
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the BacT/ALERT PZA kit in comparison with the BACTEC 460TB PZA for testing Mycobacterium tuberculosis susceptibility to pyrazinamide.
Aragón LM; Garrigó M; Moreno C; Español M; Coll P
J Antimicrob Chemother; 2007 Sep; 60(3):655-7. PubMed ID: 17615155
[TBL] [Abstract][Full Text] [Related]
20. [Specificity of antituberculous action in vitro of pyrazine-2-carboxylic acid derivatives].
Pavlov EP
Probl Tuberk; 1971; 49(7):76-9. PubMed ID: 5004351
[No Abstract] [Full Text] [Related]
[Next] [New Search]